Compare CYCU & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYCU | SERA |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.3M | 75.2M |
| IPO Year | 2021 | 2021 |
| Metric | CYCU | SERA |
|---|---|---|
| Price | $2.39 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | ★ 128.9K | 21.6K |
| Earning Date | 11-16-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,771,485.00 | $81,000.00 |
| Revenue This Year | $13.37 | $177.78 |
| Revenue Next Year | $66.84 | $755.56 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $0.01 | $1.56 |
| 52 Week High | $15.52 | $3.85 |
| Indicator | CYCU | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 55.67 |
| Support Level | $0.03 | $2.00 |
| Resistance Level | $2.77 | $2.12 |
| Average True Range (ATR) | 0.26 | 0.07 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 49.35 | 55.17 |
Cycurion Inc. provides information technology security solutions through its subsidiaries. The company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company has one reportable segment, which is the delivery of products and services in the areas of information technology, electronic warfare, information warfare and cybersecurity in the governmental and commercial markets. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.